Ignite Creation Date:
2024-05-06 @ 8:25 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06371326
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2024-04-17
First Post:
2024-04-10
Brief Title:
A Study of ZT002 Injection in Participants With Overweight or Obesity
Sponsor:
Beijing QL Biopharmaceutical CoLtd
Organization:
Beijing QL Biopharmaceutical CoLtd
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Multiple-ascending-dose Phase Ic Study Evaluating the Safety Tolerability and Pharmacokinetics of ZT002 Injection in Participants With Overweight or Obesity
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will comprise a randomized double-blind placebo-controlled multiple-ascending-dose safety tolerability and pharmacokinetics study of ZT002 in participants with Overweight or Obesity
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None